Search Medical Condition
Please enter condition
Please choose location from dropdown

Midvale, Utah Clinical Trials

A listing of Midvale, Utah clinical trials actively recruiting patient volunteers.

RESULTS

Found (406) clinical trials

A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab. The study population will consist of approximately 1050 male and female subjects aged 12 years who ...

Phase

3.2 miles

Learn More »

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

Phase

3.2 miles

Learn More »

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

Phase

3.2 miles

Learn More »

Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings

The purpose of the study is to develop a nomogram that correlates intraoperative, aphakic refraction measurements when the anterior chamber is pressurized with either balanced salt solution (BSS) or DisCoVisc; and to understand how suggested IOL power selection may differ.

Phase N/A

3.2 miles

Learn More »

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary To evaluate the safety and effect on cholestasis of two seladelpar regimens (5 mg/day titrated to 10 mg/day and 10 mg/day) over 52 weeks of treatment compared to placebo Key Secondary: To evaluate the effect of seladelpar on normalization of alkaline phosphatase (AP) levels To evaluate the effect of ...

Phase

3.2 miles

Learn More »

A Phase III Study to Evaluate the Port Delivery System Implant With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).

Phase

3.2 miles

Learn More »

Evaluation of VISITAG SURPOINT Module With External Processing Unit (EPU)

Prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT Module with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to an historical control performance goal. A maximum of 330 subjects will be enrolled across up to 45 sites. Two hundred eighty (280) enrolled subjects ...

Phase

3.2 miles

Learn More »

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System (PDS) with ranibizumab 100 mg/mL with refills administered every 24 weeks (Q24W) for approximately 144 weeks in participants with neovascular age-related macular degeneration (nAMD) who have completed either Phase II Study GX28228 or Phase III Study ...

Phase

3.2 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

Phase

3.2 miles

Learn More »

Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

The AlloSure test has been approved for Medicare coverage for clinical use when a physician determines there is a need to assess the probability of allograft rejection in kidney transplant recipients. Accurate and timely detection of allograft rejection and effective treatment are essential for long-term survival of renal transplants. The ...

Phase N/A

3.2 miles

Learn More »